Alzheimer’s disease Diagnosis and Plasma phospho-tau217-the ADAPT study

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-10-15 Abstract: Exciting progress is being made in the early and accurate detection of Alzheimer’s disease (AD) using blood tests. The most promising of these blood markers is plasma p-tau217. Dr Ashvini Keshavan will first review the evidence for concordance of plasma p-tau217 with gold standard Alzheimer’s disease biomarkers (i.e. amyloid positron emission tomography and cerebrospinal fluid tests) and the current state of commercial availability of plasma phosphorylated tau biomarkers including comparisons of effect sizes. She will then proceed with describing the plan for ADAPT, a three-stage study including a UK multi-centre randomised controlled trial of disclosure of plasma p-tau217 results to patients and clinicians. From this study she aims to find out whether plasma p-tau217 helps to diagnose AD more quickly, more accurately and at an earlier disease stage in comparison to routine memory clinic diagnostic pathways, and we will obtain evidence for its cost effectiveness and acceptability to patients. Bio: Dr Ashvini Keshavan is a senior clinical research fellow and honorary consultant neurologist at the Dementia Research Centre, UCL Queen Square Institute of Neurology. A graduate of Trinity College, Cambridge, she completed postgraduate neurology training in London, and obtained her PhD in 2019 on Cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Her ongoing work examines these biomarkers in clinical and pre-clinical cohorts, aiming toward future application in more real-world settings, serving diverse populations. She is the joint primary investigator for the UK-wide ADAPT (Alzheimer’s disease Diagnosis and Plasma p-Tau217) study. This webinar is part of the 2024 Future Blood Testing Network+ webinar series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.